Analyst Ratings For Dicerna Pharmaceuticals (NASDAQ:DRNA)
Today, Chardan Capital initiated coverage on Dicerna Pharmaceuticals (NASDAQ:DRNA) with a Neutral .
Some recent analyst ratings include
- 3/9/2018-Chardan Capital initiated coverage with a Neutral rating.
- 2/5/2018-SunTrust Banks initiated coverage with a Buy rating.
- 1/16/2018-Evercore ISI initiated coverage with a Outperform rating.
- 11/3/2017-HC Wainwright Reiterated Rating of Buy .
- 5/9/2017-Cowen Reiterated Rating of Buy.
- 4/2/2017-Jefferies Group Reiterated Rating of Buy.
Recent Insider Trading Activity For Dicerna Pharmaceuticals (NASDAQ:DRNA)
Dicerna Pharmaceuticals (NASDAQ:DRNA) has insider ownership of 29.41% and institutional ownership of 75.49%.
- On 12/18/2017 Bain Capital Life Sciences Inv, Director, bought 285,000 with an average share price of $7.00 per share and the total transaction amounting to $1,995,000.00.
- On 11/16/2016 Dennis Langer, Director, sold 23,766 with an average share price of $3.52 per share and the total transaction amounting to $83,656.32.
- On 11/15/2016 Douglas Fambrough, CEO, bought 33,100 with an average share price of $3.71 per share and the total transaction amounting to $122,801.00.
- On 5/12/2016 James B Weissman, Insider, bought 5,000 with an average share price of $3.29 per share and the total transaction amounting to $16,450.00.
- On 11/25/2014 James E Flynn, Insider, sold 321,965 with an average share price of $11.36 per share and the total transaction amounting to $3,657,522.40.
- On 11/7/2014 James E Flynn, Insider, sold 214,164 with an average share price of $9.05 per share and the total transaction amounting to $1,938,184.20.
- On 10/15/2014 James E Flynn, Insider, sold 117,778 with an average share price of $10.86 per share and the total transaction amounting to $1,279,069.08.
Recent Trading Activity for Dicerna Pharmaceuticals (NASDAQ:DRNA)
Shares of Dicerna Pharmaceuticals closed the previous trading session at 14.75 up +1.25 9.26% with 13.699999809265137 shares trading hands.